Successful treatment of a symptomatic uterine leiomyoma in a perimenopausal woman with a nonsteroidal aromatase inhibitor

Fertil Steril. 2003 Mar;79(3):628-31. doi: 10.1016/s0015-0282(02)04761-1.


Objective: To assess the management of symptomatic leiomyomas using a nonsteroidal aromatase inhibitor in perimenopausal women.

Design: Case report.

Setting: Academic clinical practice.

Patient(s): A 53-year-old woman suffering from recurrent urinary retention secondary to a uterine leiomyoma.

Intervention(s): Fadrozole, orally, 2 mg daily for 8 weeks and then 1 mg daily for 4 weeks.

Main outcome measure(s): Measurements of leiomyoma volume, and levels of serum E(2), LH, and FSH.

Result(s): Urinary retention resolved after 2 weeks of treatment and did not recur. Leiomyoma volume estimated by ultrasonography revealed a 71% reduction after 8 weeks of treatment.

Conclusion(s): Fadrozole was useful for the management of a symptomatic leiomyoma without transient deterioration of symptoms. Clinical trials are warranted.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aromatase Inhibitors*
  • Enzyme Inhibitors / therapeutic use*
  • Estradiol / blood
  • Fadrozole / administration & dosage
  • Fadrozole / therapeutic use*
  • Female
  • Follicle Stimulating Hormone / blood
  • Humans
  • Leiomyoma / drug therapy*
  • Leiomyoma / pathology
  • Luteinizing Hormone / blood
  • Menopause*
  • Middle Aged
  • Uterine Neoplasms / drug therapy*
  • Uterine Neoplasms / pathology


  • Aromatase Inhibitors
  • Enzyme Inhibitors
  • Estradiol
  • Luteinizing Hormone
  • Follicle Stimulating Hormone
  • Fadrozole